Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and α-synuclein translocation in SK-N-SH cells in culture

Developmental Neuroscience

Volumn 24, Issue 2-3, 2002, Pages 143-153

  Sangchot, P ^a,b   Sharma, S ^a   Chetsawang, B ^b   Porter, J ^a   Govitrapong, P ^b   Ebadi, Manuchair ^a,c  

^a Univ of N Dakota Sch of M   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Synuclein; Complex I; Dopamine; Iron overload; Lipid peroxidation; Mitochondria; Oxidative stress; Parkinson's disease; Substantia nigra

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEFEROXAMINE; IRON; SYNUCLEIN;

ARTICLE; CELL AGGREGATION; CELL CULTURE; CELL DEATH; CELL DISRUPTION; CELL LINE; CELL NUCLEUS MEMBRANE; CELL STRAIN; CELL STRUCTURE; CELL TRANSFORMATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ALPHA-SYNUCLEIN; CELL SURVIVAL; DEFEROXAMINE; FERRIC COMPOUNDS; HUMANS; IRON CHELATING AGENTS; LIPID PEROXIDATION; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEUROBLASTOMA; OXIDATIVE STRESS; SYNUCLEINS; TUMOR CELLS, CULTURED;

EID: 0036970672     PISSN: 03785866     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065700     Document Type: Article

References (24)

1. Aoki S, Okada Y, Nishimura K: Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology 1989;172: 381-385.
2. Baysal E, Monteiro HP, Sullivan SG, Stern A: Des-ferrioxamine protects human red blood cells from hemin-induced hemolysis. Free Rad Biol Med 1990;9:5-10.
3. Beard JL, Connor JR, Jones BC: Iron in the brain. Nutr Rev 1993;51:157-170.
4. Blake DR, Hall ND, Baron A, Dieppe PA, Halli-well B, Gutteridge JMC: Effect of specific iron chelating agents on animal models of inflammation. Ann Rheum Dis 1983;42:89-93.
5. Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Mol Biol 1998;108:302-310.
6. Clark IA, Hunt NH: Evidence for reactive oxygen intermediates causing hemolysis and parasite death in malaria. Infect Immun 1983;39:1-6.
7. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD: Alterations in the levels of iron, ferritin, and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114: 1953-1975.
8. Ebadi M, Srinivasan S, Baxi M: Oxidative stress and antioxidant therapy in Parkinson's disease. Progr Neurobiol 1996;48:1-19.
9. Ebadi M, Govitrapong P, Sharma S, Muralikrish-nan D, Shavali S, Pellett L, Schafer R, Albano C, Eken J: Ubiquinone (Coenzyme Q10) and mitochondria in oxidative stress of Parkinson's disease. Biol Signals Recept 2001;10:224-253.
10. Ebadi M, Hiramatsu M: Glutathione and metallo-thionein in oxidative stress of Parkinson's disease; in Poli G, Cadenas E (eds): Free Radicals in Brain Pathophysiology. New York, Marcel Dekker, 2000, pp 427-465.
11. Emerit J, Beaumont C, Trivin F: Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 2001;55:333-339.
12. Freedman MH, Boyden M, Taylor M, Skarf B: Neurotoxicity associated with deferoxamine therapy. Toxicology 1988;49:283-290.
13. Grankvist K, Marklund SL: Opposite effects of two metalchelators on alloxan-induced diabetes in mice. Life Sci 1983;33:2535-2540.
14. Gutteridge JMC, Richmond R, Halliwell B: Inhibition of iron-catalysed formation of hydroxyl radicals from super-oxide and lipid peroxidation by desferrioxamine. Biochem 1979;184: 469-472.
15. Hallgren B, Sourander P: The effect of age on the nonhaemin iron in the human brain. J Neuro-chem 1958;3:41-51.
16. Jellinger KA: The role of iron in neurodegenera-tion: Prospects for pharmacotherapy of Parkin-son's disease. Drugs Aging 1999;14:115-140.
17. LeVine RL, Garland D, Oliver CN, Amici A, Cli-ment I, Lenz AG, Ahn S, Shaltiel S, Stadtman ER: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-478.
18. Nelson SK, McCord JM: Iron, oxygen radicals, and disease. Adv Mol Cell Biol 1998;25:157-183.
19. Reddy BR, Kloner RA, Przyklenk K: Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Rad Biol Med 1985;7:45-52.
20. Sinaceur R, Ribiere C, Abu-Murad C, Nordmann J, Nordmann R: Reduction in the rate of ethanol elimination in vivo by desferrioxamine and diethylenetrimine penta acetic acid: Suggestion for involvement of hydroxyl radicals in ethanol oxidation. Biochem Pharm 1983;32:2371-2373.
21. Uversky VN, Li J, Fink AL: Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein: A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem 2001;276:44284-44296.
22. Ward PA, Till GO, Kundel R, Beauchamp C: Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest 1983;72:789-801.
23. Willis ED: Lipid peroxide formation in micro-somes: The role of non-haem iron. Biochem 1969;113:325-332.
24. Wu GS, Walker J, Rao NA: Effect of deferoxamine on retinal lipid peroxidation in experimental uveitis. Invest Ophthalmol Vis Sci 1993;34: 3084-3089.